Abstract
The last decade has seen the emergence of a shift in paradigm in the therapeutic strategies to target cancer. This is based on the existence of a small reservoir of cells within the tumor mass that exhibits the capacity for self-renewal, as well as undergo differentiation to give rise to phenotypically heterogeneous progeny with limited proliferative potential. These stem-like cells likely drive the continued growth of the tumor mass and are capable of disseminating and are subsequently metastasized. Relapse is probably orchestrated by the post-therapy residual drug-resistant "cancer stem" cells that escape treatment. Therefore, the selective targeting of cancer stem cells is supposed to offer radical advances in the treatment and diagnosis of lung cancer. This chapter will discuss the emerging data supporting the validity of this notion and consider the growing evidence that cancer stem cells may contribute to tumor progression, drug resistance, metastasis, and speculates about how taking these cells into consideration may affect the way we treat lung cancer in the future.
| Original language | English (US) |
|---|---|
| Title of host publication | Lung Cancer Metastasis: Novel Biological Mechanisms and Impact on Clinical Practice |
| Publisher | Springer New York |
| Pages | 47-63 |
| Number of pages | 17 |
| ISBN (Print) | 9781441907714 |
| DOIs | |
| State | Published - 2009 |
Fingerprint
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
Cite this
Tumor stem cells and metastasis. / Hung, Jaclyn Y.
Lung Cancer Metastasis: Novel Biological Mechanisms and Impact on Clinical Practice. Springer New York, 2009. p. 47-63.Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - Tumor stem cells and metastasis
AU - Hung, Jaclyn Y.
PY - 2009
Y1 - 2009
N2 - The last decade has seen the emergence of a shift in paradigm in the therapeutic strategies to target cancer. This is based on the existence of a small reservoir of cells within the tumor mass that exhibits the capacity for self-renewal, as well as undergo differentiation to give rise to phenotypically heterogeneous progeny with limited proliferative potential. These stem-like cells likely drive the continued growth of the tumor mass and are capable of disseminating and are subsequently metastasized. Relapse is probably orchestrated by the post-therapy residual drug-resistant "cancer stem" cells that escape treatment. Therefore, the selective targeting of cancer stem cells is supposed to offer radical advances in the treatment and diagnosis of lung cancer. This chapter will discuss the emerging data supporting the validity of this notion and consider the growing evidence that cancer stem cells may contribute to tumor progression, drug resistance, metastasis, and speculates about how taking these cells into consideration may affect the way we treat lung cancer in the future.
AB - The last decade has seen the emergence of a shift in paradigm in the therapeutic strategies to target cancer. This is based on the existence of a small reservoir of cells within the tumor mass that exhibits the capacity for self-renewal, as well as undergo differentiation to give rise to phenotypically heterogeneous progeny with limited proliferative potential. These stem-like cells likely drive the continued growth of the tumor mass and are capable of disseminating and are subsequently metastasized. Relapse is probably orchestrated by the post-therapy residual drug-resistant "cancer stem" cells that escape treatment. Therefore, the selective targeting of cancer stem cells is supposed to offer radical advances in the treatment and diagnosis of lung cancer. This chapter will discuss the emerging data supporting the validity of this notion and consider the growing evidence that cancer stem cells may contribute to tumor progression, drug resistance, metastasis, and speculates about how taking these cells into consideration may affect the way we treat lung cancer in the future.
UR - http://www.scopus.com/inward/record.url?scp=84900607522&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84900607522&partnerID=8YFLogxK
U2 - 10.1007/978-1-4419-0772-1_3
DO - 10.1007/978-1-4419-0772-1_3
M3 - Chapter
AN - SCOPUS:84900607522
SN - 9781441907714
SP - 47
EP - 63
BT - Lung Cancer Metastasis: Novel Biological Mechanisms and Impact on Clinical Practice
PB - Springer New York
ER -